Cargando…
Efficacy of a Pseudomonas aeruginosa Serogroup O9 Vaccine
There are currently no approved vaccines against the opportunistic pathogen Pseudomonas aeruginosa. Among vaccine targets, the lipopolysaccharide (LPS) O antigen of P. aeruginosa is the most immunodominant protective candidate. There are twenty different O antigens composed of different repeat sugar...
Autores principales: | Moustafa, Dina A., DiGiandomenico, Antonio, Raghuram, Vishnu, Schulman, Marc, Scarff, Jennifer M., Davis,, Michael R., Varga, John J., Dean, Charles R., Goldberg, Joanna B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369961/ https://www.ncbi.nlm.nih.gov/pubmed/37502855 http://dx.doi.org/10.1101/2023.07.13.548830 |
Ejemplares similares
-
Draft Genome Sequences of Eight Pseudomonas aeruginosa Corneal Infection Isolates
por: Raghuram, Vishnu, et al.
Publicado: (2020) -
Multifunctional Monoclonal Antibody Targeting Pseudomonas aeruginosa Keratitis in Mice
por: Hebert, Wesley, et al.
Publicado: (2020) -
Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders
por: Moustafa, Dina A., et al.
Publicado: (2015) -
Staphylococcus aureus and Pseudomonas aeruginosa Isolates from the Same Cystic Fibrosis Respiratory Sample Coexist in Coculture
por: Bernardy, Eryn E., et al.
Publicado: (2022) -
A Pseudomonas aeruginosa-Derived Particulate Vaccine Protects against P. aeruginosa Infection
por: Gonzaga, Zennia Jean C., et al.
Publicado: (2021)